{
    "nct_id": "NCT03686124",
    "official_title": "Phase 1 Study Evaluating Genetically Modified Autologous T Cells Expressing a TCR Recognizing a Cancer/Germline Antigen as Monotherapy or in Combination With Nivolumab in Patients With Recurrent and/or Refractory Solid Tumors",
    "inclusion_criteria": "* Patients must have recurrent/progressing and/or refractory solid tumors and must have received or not be eligible for all available indicated standard of care treatment.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n* HLA-A*02:01 positive\n* Measurable disease according to RECIST 1.1\n* Adequate selected organ function per protocol\n* Patient's tumor must express tumor antigen by \"IMADetectÂ® RT-qPCR\n* Life expectancy more than 5 months\n* Female patient of childbearing potential must use adequate contraception prior to study entry until 12 months after the infusion of IMA203/IMA203CD8\n* Male patient must agree to use effective contraception or be abstinent while on study and for 6 months after the infusion of IMA203/IMA203CD8\n* The patient must have recovered from any side effects of prior therapy to Grade 1 or lower prior to lymphodepletion.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) within the last 3 years\n* Pregnant or breastfeeding\n* Serious autoimmune disease Note: At the discretion of the investigator, these patients may be included if their disease is well controlled without the use of immunosuppressive agents.\n* History of cardiac conditions as per protocol\n* Prior stem cell transplantation or solid organ transplantation\n* Concurrent severe and/or uncontrolled medical disease that could compromise participation in the study\n* History of or current immunodeficiency disease or prior treatment compromising immune function at the discretion of the treating physician\n* Positive for HIV infection or with active hepatitis B virus (HBV) or active hepatitis C virus (HCV) infection.\n* Patients with LDH greater than 2.0-fold ULN.\n* Any condition contraindicating leukapheresis, lymphodepletion, low-dose IL-2, and/or IMA203/IMA203CD8 treatment\n* Patients with active brain metastases\n* Concurrent treatment in another clinical trial.\n* For nivolumab treatment, patients must not have a history of severe immune-related toxicities, defined as any Grade 3 or 4 toxicities related to prior PD1/PD-L1 inhibitor therapy (e.g., atezolizumab, pembrolizumab or nivolumab etc.).\n\nOther protocol defined inclusion/exclusion criteria could apply",
    "miscellaneous_criteria": ""
}